

Cabozantinib Development Program

Discovered by Exelixis, and the focus of our development and commercialization efforts, Cabozantinib inhibits the activity of tyrosine kinases including MET, AXL, VEGF

receptors, and RET and is recognized for its potential to treat a wide variety of cancers.

[Download the PDF.](#)

R & D

Pipeline Overview

Early-Stage Compounds

Cabozantinib Pipeline

Other Partnered Programs

Clinical Trials

Filter by Therapeutic Area

- ☐ Adrenal Tumors
- ☐ Adrenocortical Carcinoma
- ☐ Any GU Tumors
- ☐ Bladder Cancer
- ☐ Breast Cancer
- ☐ Colorectal Cancer (CRC)
- ☐ Differentiated Thyroid Cancer (DTC)
- ☐ Endometrial Cancer
- ☐ Esophageal Cancer
- ☐ Gastroesophageal Cancer
- ☐ Gastrointestinal (GI) Cancers
- ☐ Gastrointestinal Stromal Tumor (GIST)
- ☐ Genitourinary (GU) Cancers
- ☐ Germ Cell Tumors
- ☐ Gynecologic Cancers
- ☐ Head and Neck Cancer
- ☐ Hepatocellular Carcinoma (HCC)
- ☐ Lung Cancer
- ☐ Melanoma
- ☐ Mesothelioma
- ☐ Multiple Solid Tumor Types
- ☐ Neuroendocrine Tumors (NET) & Carcinoid
- ☐ Neurofibroma
- ☐ Non-Small Cell Lung Cancer
- ☐ Ovarian Cancer
- ☐ Pancreatic Cancer
- ☐ Pediatric Cancer
- ☐ Pediatric Glioma
- ☐ Pediatric Multiple Tumor Types
- ☐ Pediatric Neurofibroma
- ☐ Pediatric Sarcoma
- ☐ Prostate Cancer
- ☐ Rare GU Tumors
- ☐ Renal Cell Carcinoma (RCC)
- ☐ Sarcoma
- ☐ Squamous Cell Carcinoma
- ☐ Thyroid Cancer
- ☐ Urothelial Carcinoma (UC)

[Clear Filters](#)

Exelixis-Sponsored Trial Roche-Sponsored Trial Bristol Myers Squibb-Sponsored Trial Investigator-Sponsored Trial Collaboration with HCL Cancer Therapy Evaluation Program Sponsored by the European Organisation for Research and Treatment of Cancer (EORTC)

PHASE 1 PHASE 2 PHASE 3

Genitourinary (GU) Cancers

Cabozantinib + Nivolumab +/- CBM588 (Metastatic RCC)	Cabozantinib (Refractory Germ Cell Tumors)	CONTACT-03: Cabozantinib + Atezolizumab vs. Cabozantinib (Isolated RCC)
Renal Cell Cancer	Germ Cell Tumors	Renal Cell Carcinoma
CABIOS: Cabozantinib + Abiraterone + Nivolumab (Metastatic Hormone-Sensitive Prostate Cancer)	Cabozantinib (Metastatic CRPC with Genomic Alterations)	CONTACT-02: Cabozantinib + Atezolizumab vs. Second Novel Hormone Therapy (Metastatic, Castrax-resistant PC)
Prostate Cancer	Prostate Cancer	Prostate Cancer
Cabozantinib + Enfortumab Vedotin (Locally Advanced or Metastatic UC)	Cabozantinib + Nivolumab + Ipilimumab (Advanced Non-Clear Cell Renal Carcinoma)	COSMIC-313: Cabozantinib + Nivolumab + Ipilimumab (First-line Advanced or Metastatic RCC)
Urothelial Carcinoma	Renal Cell Carcinoma	Renal Cell Carcinoma
COSMIC-021: Cabozantinib (Advanced UC)	Cyto-KiK: CYTO Reductive Surgery followed by Cabozantinib + Nivolumab (Metastatic RCC)	PDIGREE: Nivolumab + Ipilimumab followed by Cabozantinib + Nivolumab vs. Nivolumab (First-line Metastatic RCC)
Urothelial Carcinoma	Renal Cell Carcinoma	Renal Cell Carcinoma
COSMIC-021: Cabozantinib + Atezolizumab (Advanced RCC, Advanced UC, & CRPC)	ABATE: Cabozantinib + Atezolizumab (Muscle-Invasive Bladder Cancer)	
Renal Cell Carcinoma / Urothelial Carcinoma / Prostate Cancer	Bladder Cancer	
Cabozantinib + Nivolumab + Ipilimumab	PemCab: Cabozantinib + Pembrolizumab (Metastatic UC Ineligible for Cisplatin)	
Any GU Tumors	Bladder Cancer / Urothelial Carcinoma	
Cabozantinib + Avelumab (Metastatic Renal Cell Carcinoma)	RadiCAL: Cabozantinib + Radium-223 Dichloride (Advanced RCC with Bone Metastasis)	
Renal Cell Carcinoma	Renal Cell Carcinoma	
	Cabozantinib (Advanced or Metastatic Urothelial Carcinoma)	
	Urothelial Carcinoma	
	Cabozantinib (Clear Cell or Non-Clear Cell Metastatic RCC)	
	Renal Cell Carcinoma	
	ATLANTIS: Cabozantinib (Metastatic Urothelial Carcinoma)	
	Urothelial Carcinoma	

Gastrointestinal (GI) Cancers

Cabozantinib + TAS-102 (Metastatic Colorectal Adenocarcinoma)	Cabozantinib + Pembrolizumab (Metastatic Pancreatic Adenocarcinoma)	COSMIC-312: Cabozantinib + Atezolizumab vs. Sorafenib vs. Cabozantinib (First-line Advanced or Metastatic HCC)
Colorectal Carcinoma	Pancreatic Cancer	Hepatocellular Carcinoma
CAMILLA: Cabozantinib + Durvalumab (Advanced CRC & HCC)	Cabozantinib + Atezolizumab (Metastatic, Refractory Pancreatic Cancer)	
Colorectal Cancer / Hepatocellular Carcinoma	Pancreatic Cancer	
Cabozantinib + Nivolumab (Neoadjuvant, Locally Advanced HCC)	Cabozantinib + Nivolumab (Refractory Metastatic Nodules Stable CRC)	
Hepatocellular Carcinoma	Colorectal Carcinoma	
COSMIC-021: Cabozantinib + Atezolizumab (HCC & CRC)	Cabozantinib + Pembrolizumab (Advanced HCC)	
Colorectal Cancer / Hepatocellular Carcinoma	Hepatocellular Carcinoma	
	Cabozantinib + Nivolumab + Ipilimumab and TACE (Hepatocellular Carcinoma)	
	Hepatocellular Carcinoma	
	Cabozantinib (Advanced hepatocellular carcinoma with Child-Pugh Class A cirrhosis after First-Line Therapy)	
	Hepatocellular Carcinoma	
	CheckMate 040 Subgroup: Cabozantinib + Nivolumab + Ipilimumab (First-line and previously treated Advanced HCC)	
	Hepatocellular Carcinoma	
	Cabozantinib (Refractory, Metastatic CRC)	
	Colorectal Cancer	
	Cabozantinib + Pembrolizumab (Metastatic or Recurrent Gastric or Gastro-Esophageal Adenocarcinoma)	
	Gastric or Gastro-Esophageal Cancer	

Thyroid Cancer

COSMIC-021: Cabozantinib + Atezolizumab (DTC)	Cabozantinib (First-line, RA-refractory DTC)
Differentiated Thyroid Cancer	Differentiated Thyroid Cancer

Lung Cancer

COSMIC-021: Cabozantinib (NSCLC)	Cabozantinib vs. Cabozantinib + Nivolumab vs. Chemotherapy (Previously Treated Non-Squamous NSCLC)	CONTACT-01: Cabozantinib + Atezolizumab vs. Docetaxel (Refractory NSCLC)
Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer
COSMIC-021: Cabozantinib + Atezolizumab (NSCLC)	Cabozantinib (Molecular Alterations in RET, ROS1, MET, AXL, or NTRK3)	
Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	
	Nivolumab vs. Cabozantinib + Nivolumab vs. Cabozantinib + Nivolumab + Ipilimumab (NSCLC)	
	Non-Small Cell Lung Cancer	

Gynecologic Cancers

COSMIC-021: Cabozantinib + Atezolizumab (EC, Ovarian Cancer & Breast Cancer)	Nivolumab + Cabozantinib (Advanced or Metastatic EC)
Breast Cancer / Ovarian Cancer / Endometrial Cancer	Endometrial Cancer

Neuroendocrine Tumors (NET) & Carcinoid

Cabozantinib (Neuroendocrine Neoplasms)	CABINET: Cabozantinib vs. Placebo (Advanced Neuroendocrine Tumors After Progression on Everolimus)
NET & Carcinoid	NET & Carcinoid
Cabozantinib + Nivolumab + Ipilimumab (Poorly Differentiated Neuroendocrine Carcinoma)	
NET & Carcinoid	
Cabozantinib + Nivolumab (Advanced Carcinoid Tumors)	
NET & Carcinoid	
Cabozantinib (Advanced Pancreatic NET & Advanced Carcinoid)	
NET & Carcinoid	

Adrenocortical Carcinoma

Cabozantinib (Metastatic Pheochromocytomas and Paragangliomas)	
Adrenal Tumors	
Cabozantinib (Metastatic Adrenocortical Carcinoma)	
Adrenal Tumors	

Sarcoma

Cabozantinib + Nivolumab (Taxane Pre-treated) vs. Pazisaxel + Nivolumab (Taxane Naïve) (Angiosarcoma)	
Sarcoma	
Cabozantinib + PD-1 and CTLA-4 Inhibition (Metastatic Soft Tissue Sarcoma)	
Sarcoma	
Cabozantinib + Radiation Therapy (Sarcomas of the Extremities)	
Sarcoma	
Cabozantinib + Temozolomide (Unresectable or Metastatic Leiomyosarcoma and other Soft Tissue Sarcoma)	
Sarcoma	
Cabozantinib vs. Placebo (High-Grade Uterine Sarcoma)	
Sarcoma	
Cabozantinib (Metastatic Soft Tissue Sarcoma)	
Sarcoma	

Neurofibroma

Cabozantinib in Plexiform Neurofibromas	
Neurofibroma	

Gastroesophageal Cancer

CAMILLA: Cabozantinib + Durvalumab (Advanced Gastric, Gastroesophageal or Esophageal Adenocarcinoma)	
Gastroesophageal Cancer / Esophageal Cancer	
COSMIC-021: Cabozantinib + Atezolizumab (Gastric or Gastroesophageal Junction Adenocarcinoma)	
Gastroesophageal Cancer	

Head and Neck Cancer

Cabozantinib + Cetuximab (Recurrent, Metastatic Squamous Cell Carcinoma)	Cabozantinib + Pembrolizumab (Recurrent, Metastatic Squamous Cell Carcinoma)
Squamous Cell Carcinoma	Squamous Cell Carcinoma
COSMIC-021: Cabozantinib + Atezolizumab (Head and Neck Cancer)	
Head and Neck Cancer	

Melanoma

Cabozantinib + Pembrolizumab (Advanced, Metastatic Melanoma)	
Melanoma	
Cabozantinib + Nivolumab + Ipilimumab (Unresectable, Advanced Melanoma)	
Melanoma	

Multiple Solid Tumor Types

Cabozantinib + Pemetrexed (Advanced Non-Squamous NSCLC, UC, and Advanced Malignant Mesothelioma)	
Non-Small Cell Lung Cancer / Urothelial Carcinoma / Mesothelioma	
Cabozantinib + Pamiparib (Advanced Solid Tumors)	
Advanced Solid Tumors	
Cabozantinib + Nivolumab (Multiple Solid Tumor Types and HIV)	
Multiple Solid Tumor Types / HIV	

Pediatric Cancer

Cabozantinib + Retinoic Acid	CaboMain: Cabozantinib (High-risk Pediatric Solid Tumors)
Pediatric Multiple Tumor Types	Pediatric Multiple Tumor Types
	Cabozantinib in Plexiform Neurofibromas
	Pediatric Neurofibroma
	Cabozantinib (High-grade Pediatric Glioma)
	Pediatric Glioma
	CARDONE: Cabozantinib (Pediosarcomas and Ewing Sarcomas; Patients 124)
	Pediatric Sarcoma
	Cabozantinib (Refractory Sarcoma, Wilms Tumor, Other Rare Tumors)
	Pediatric Multiple Tumor Types

Other Partnered Compounds

We are also advancing cancer treatment through collaborations.

[LEARN MORE >](#)

OUR STORY

Mission
Leadership
Board of Directors
Collaborations

MEDICINES

Our Medicines
Access

RESEARCH & DEVELOPMENT

Research & Development
Pipeline
Clinical Trials

IMPACT

Why Cancer?
Patient Stories
Grants & Giving
Corporate Responsibility
Environmental, Social & Governance
Statement on COVID-19

INVESTORS & MEDIA

Investors Overview
Stock Information
Investor Resources
Contact IR
News & Events
Financial Information
Corporate Governance